Metabolomic studies in the inborn error of metabolism alkaptonuria reveal new biotransformations in tyrosine metabolism

[1]  J. Jarvis,et al.  Efficacy and safety of once-daily nitisinone for patients with alkaptonuria (SONIA 2): an international, multicentre, open-label, randomised controlled trial. , 2020, The lancet. Diabetes & endocrinology.

[2]  J. Jarvis,et al.  Homogentisic acid is not only eliminated by glomerular filtration and tubular secretion but also produced in the kidney in alkaptonuria , 2020, Journal of inherited metabolic disease.

[3]  H. Oschkinat,et al.  Pigmentation Chemistry and Radical‐Based Collagen Degradation in Alkaptonuria and Osteoarthritic Cartilage , 2020, Angewandte Chemie.

[4]  George Bou-Gharios,et al.  Conditional targeting in mice reveals that hepatic homogentisate 1,2-dioxygenase activity is essential in reducing circulating homogentisic acid and for effective therapy in the genetic disease alkaptonuria , 2019, Human molecular genetics.

[5]  L. Ranganath,et al.  Ochronotic pigmentation is caused by homogentisic acid and is the key event in alkaptonuria leading to the destructive consequences of the disease—A review , 2019, Journal of inherited metabolic disease.

[6]  A. Milan,et al.  Evaluation of the serum metabolome of patients with alkaptonuria before and after two years of treatment with nitisinone using LC‐QTOF‐MS , 2019, JIMD reports.

[7]  George Bou-Gharios,et al.  Assessing the effect of nitisinone induced hypertyrosinaemia on monoamine neurotransmitters in brain tissue from a murine model of alkaptonuria using mass spectrometry imaging , 2019, Metabolomics.

[8]  J. Jarvis,et al.  A Comprehensive LC-QTOF-MS Metabolic Phenotyping Strategy: Application to Alkaptonuria. , 2019, Clinical chemistry.

[9]  B. Kestenbaum,et al.  Metabolomics and Gene Expression Analysis Reveal Down-regulation of the Citric Acid (TCA) Cycle in Non-diabetic CKD Patients , 2017, EBioMedicine.

[10]  L. Ranganath,et al.  The effect of nitisinone on homogentisic acid and tyrosine: a two-year survey of patients attending the National Alkaptonuria Centre, Liverpool , 2017, Annals of clinical biochemistry.

[11]  L. Ranganath,et al.  Acute fatal metabolic complications in alkaptonuria , 2016, Journal of Inherited Metabolic Disease.

[12]  F. Cotton,et al.  Renal and prostate stones composition in alkaptonuria: a case report. , 2015, Clinical nephrology.

[13]  Annalisa Santucci,et al.  Oxidative stress and mechanisms of ochronosis in alkaptonuria. , 2015, Free radical biology & medicine.

[14]  N. Vaziri,et al.  Metabolomics insights into chronic kidney disease and modulatory effect of rhubarb against tubulointerstitial fibrosis , 2015, Scientific Reports.

[15]  J. Jarvis,et al.  Nitisinone Arrests but Does Not Reverse Ochronosis in Alkaptonuric Mice. , 2015, JIMD reports.

[16]  Guangyao Chen,et al.  Intratumoral estrogen sulfotransferase induction contributes to the anti-breast cancer effects of the dithiocarbamate derivative TM208 , 2015, Acta Pharmacologica Sinica.

[17]  A. Davies,et al.  Untargeted UPLC-MS Profiling Pipeline to Expand Tissue Metabolome Coverage: Application to Cardiovascular Disease , 2015, Analytical chemistry.

[18]  L. Ranganath,et al.  Serum markers in alkaptonuria: simultaneous analysis of homogentisic acid, tyrosine and nitisinone by liquid chromatography tandem mass spectrometry , 2015, Annals of clinical biochemistry.

[19]  A. Chakrapani,et al.  Outcome of children with hereditary tyrosinaemia following newborn screening , 2015, Archives of Disease in Childhood.

[20]  Andrea Zatkova,et al.  Suitability Of Nitisinone In Alkaptonuria 1 (SONIA 1): an international, multicentre, randomised, open-label, no-treatment controlled, parallel-group, dose-response study to investigate the effect of once daily nitisinone on 24-h urinary homogentisic acid excretion in patients with alkaptonuria afte , 2014, Annals of the rheumatic diseases.

[21]  L. Ranganath,et al.  Urine homogentisic acid and tyrosine: simultaneous analysis by liquid chromatography tandem mass spectrometry. , 2014, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

[22]  David S. Wishart,et al.  CFM-ID: a web server for annotation, spectrum prediction and metabolite identification from tandem mass spectra , 2014, Nucleic Acids Res..

[23]  R. Tukey,et al.  Importance of UDP-Glucuronosyltransferase 1A1 Expression in Skin and Its Induction by UVB in Neonatal Hyperbilirubinemia , 2013, Molecular Pharmacology.

[24]  Dominic P. Williams,et al.  Ochronotic osteoarthropathy in a mouse model of alkaptonuria, and its inhibition by nitisinone , 2013, Annals of the rheumatic diseases.

[25]  J. Jarvis,et al.  Recent advances in management of alkaptonuria (invited review; best practice article) , 2013, Journal of Clinical Pathology.

[26]  Duolong Di,et al.  Metabolite target analysis of human urine combined with pattern recognition techniques for the study of symptomatic gout. , 2012, Molecular bioSystems.

[27]  Dominic P. Williams,et al.  Pharmacological and Toxicological Considerations of Homogentisic Acid in Alkaptonuria , 2012 .

[28]  K. Knights,et al.  Amino Acid Conjugation: A Novel Route of Xenobiotic Carboxylic Acid Metabolism in Man , 2011 .

[29]  A. Boyde,et al.  The role of calcified cartilage and subchondral bone in the initiation and progression of ochronotic arthropathy in alkaptonuria. , 2011, Arthritis and rheumatism.

[30]  J. Troendle,et al.  A 3-year randomized therapeutic trial of nitisinone in alkaptonuria. , 2011, Molecular genetics and metabolism.

[31]  A. Zatkova,et al.  An update on molecular genetics of Alkaptonuria (AKU) , 2011, Journal of Inherited Metabolic Disease.

[32]  M. Keshavan,et al.  Homeostatic Imbalance of Purine Catabolism in First-Episode Neuroleptic-Naïve Patients with Schizophrenia , 2010, PloS one.

[33]  T. Helliwell,et al.  Alkaptonuria – a review of surgical and autopsy pathology , 2008, Histopathology.

[34]  J. P. Telo,et al.  Structure and redox properties of radicals derived from one-electron oxidised methylxanthines , 2008, Redox report : communications in free radical research.

[35]  K. Knights,et al.  Amino acid conjugation: contribution to the metabolism and toxicity of xenobiotic carboxylic acids , 2007, Expert opinion on drug metabolism & toxicology.

[36]  R. Mortishire-Smith,et al.  Automated assignment of high‐resolution collisionally activated dissociation mass spectra using a systematic bond disconnection approach , 2005 .

[37]  William A Gahl,et al.  Natural history of alkaptonuria. , 2002, The New England journal of medicine.

[38]  P. Olinga,et al.  Drug-metabolizing activity of human and rat liver, lung, kidney and intestine slices , 2002, Xenobiotica; the fate of foreign compounds in biological systems.

[39]  A. Moskowitz,et al.  Purine catabolism: links to mitochondrial respiration and antioxidant defenses? , 1999, Archives of biochemistry and biophysics.

[40]  J. Fahey,et al.  Antioxidant functions of sulforaphane: a potent inducer of Phase II detoxication enzymes. , 1999, Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association.

[41]  J. Deutsch,et al.  Quantitation of homogentisic acid in normal human plasma. , 1996, Journal of chromatography. B, Biomedical applications.

[42]  U. Nayak,et al.  Homogentisic acid and structurally related compounds as intermediates in plasma soluble melanin formation and in tissue toxicities. , 1994, Archives internationales de physiologie, de biochimie et de biophysique.

[43]  G. Siest,et al.  The UDP glucuronosyltransferase gene superfamily: suggested nomenclature based on evolutionary divergence. , 1991, DNA and cell biology.

[44]  P. Talalay,et al.  Identification of a common chemical signal regulating the induction of enzymes that protect against chemical carcinogenesis. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[45]  T. Woolf,et al.  Basic Concepts in Drug Metabolism: Part II , 1987, Journal of clinical pharmacology.

[46]  T. Woolf,et al.  Basic Concepts in Drug Metabolism: Part I , 1987, Journal of clinical pharmacology.

[47]  R. T. Williams.  THE METABOLISM OF CERTAIN DRUGS AND FOOD CHEMICALS IN MAN * , 1971, Annals of the New York Academy of Sciences.

[48]  L. Ranganath,et al.  Assessment of the Effect of Once Daily Nitisinone Therapy on 24-h Urinary Metadrenalines and 5-Hydroxyindole Acetic Acid Excretion in Patients with Alkaptonuria After 4 Weeks of Treatment. , 2018, JIMD reports.

[49]  L. Ranganath,et al.  Serum Amino Acid Profiling in Patients with Alkaptonuria Before and After Treatment with Nitisinone. , 2018, JIMD reports.

[50]  L. Ranganath,et al.  Relationship Between Serum Concentrations of Nitisinone and Its Effect on Homogentisic Acid and Tyrosine in Patients with Alkaptonuria. , 2015, JIMD reports.

[51]  D. Assimos,et al.  Hypocitraturia: pathophysiology and medical management. , 2009, Reviews in urology.

[52]  R. Tukey,et al.  Human UDP-glucuronosyltransferases: metabolism, expression, and disease. , 2000, Annual review of pharmacology and toxicology.

[53]  S. R. Spencer,et al.  The electrophile counterattack response: protection against neoplasia and toxicity. , 1993, Advances in enzyme regulation.

[54]  T. Woolf,et al.  Basic concepts in drug metabolism.II , 1987 .